The vast majority of drugs that drug companies seriously pursue are good, and the delay imposed by the approval process means that the cost, in lives of people who could have benefited earlier and some who died, is overwhelming compared to the benefit of screening out inefficacious or unsafe drugs, so Peltzman concludes that this kind of regulation kills more people than it saves.

causalpending

Speaker

Sam Peltzman

Evidence Quote

“my binding was you know to cut to the chase this kind of regulation kills more people than it saves”

Source

Peltzman on Regulation 11/13/2006— EconTalk
Created: 11/11/2026, 5:13:30 AM

Your notes

Loading notes...